NCCN TRENDS Results: January 2013 NCCN Trends is an analytics tool from the National Comprehensive Cancer Network (NCCN ) that surveys how clinicians across the U.S. and around the globe are delivering cancer care. This summary includes the results of the January 2013 NCCN Trends Survey, which focused on Non-Small Cell Lung Cancer. This survey was sent to U.S. and International users of NCCN.org. DEMOGRAPHICS Distribution of Respondent Types (n = 1,055) 14% Physician/Surgeon/Oncologist Nurse/Oncology Nurse or Clinical Nurse Specialist 7 4% 4% Pharmacist Physician Assistant or Nurse Practitioner Other Clinician Page 1
Q1. Do you treat patients with non-small cell lung cancer (NSCLC) and treat them according to a pathway program which is driven by either a practice, a hospital, an accountable care organization, or a payer? (n = 1,055) 6 3 Yes, I treat patients with NSCLC according to one of the above pathways No Page 2
Q2. According to which types of pathways do you currently practice? (select all that apply) (n = 534) Practice 4 Hospital 6 Accountable care organization 1 Payer 0% 20% 30% 40% 50% 60% 70% 80% Page 3
Q2. According to which types of pathways do you currently practice? (select all that apply) By Geography US Midwest US Northeast US South US West Europe Latin America Asia Other Non-US Practice (n=253) 12% 12% 1 1 1 Hospital (n=354) 3 2 Accountable care organization (n=66) 21% 2 Payer (n=40) 1 3 1 1 Note: Percentages may not total 100 because of rounding. Page 4
Q2. According to which types of pathways do you currently practice? (select all that apply) By Practice Size 1 to 3 4 to 9 10 or more Practice (n=253) 20% 2 54% Hospital (n=354) 22% 22% 5 Accountable care organization (n=66) 1 2 5 Payer (n=40) 1 30% 5 Note: Percentages may not total 100 because of rounding. Page 5
Q2. According to which types of pathways do you currently practice? (select all that apply) By Practice Setting Academic Setting Community Setting Practice (n=247) 4 5 Hospital (n=351) 6 3 Accountable care organization (n=64) 4 52% Payer (n=39) 44% 5 Page 6
Q2. According to which types of pathways do you currently practice? (select all that apply) By Specialty Medical Oncology Radiation Oncology Surgical Oncology Internal Medicine General Surgery Other Practice (n=253) 60% 14% 2% 12% Hospital (n=354) 4 2 2% 14% Accountable care organization (n=66) 5 21% 11% Payer (n=40) 7 1 Note: Percentages may not total 100 because of rounding. Page 7
Q3. Which statement best reflects your use of guidelines or pathways when treating 1st line, stage IV, non-squamous NSCLC patients? (select all that apply) (n = 519) Limited guideline or pathway is defined as 3 options or less for a specific cancer. (e.g.: Stage IV, non-squamous NSCLC) our practice approved pathway. 4 an approved guideline for the hospital I work within. 3 an approved guideline for the accountable care organization (ACO) I work within. 12% enhance my reimbursement if I meet their threshold. decrease my reimbursement if I don t meet their threshold. I am not expected by the organization I work within, to comply with any set guidelines or pathways when treating nonsquamous NSCLC patients. 14% 0% 20% 30% 40% 50% 60% Page 8
Q3. Which statement best reflects your use of guidelines or pathways when treating 1st line, stage IV, non-squamous NSCLC patients? (select all that apply) Limited guideline or pathway is defined as 3 options or less for a specific cancer. (e.g.: Stage IV, non-squamous NSCLC) By Geography US Midwest US Northeast US South US West Europe Latin America Asia Other Non-US our practice approved pathway. (n=254) 1 2 22% 4% an approved guideline for the hospital I work within. (n=192) 4% 34% 2 an approved guideline for the accountable care organization (ACO) I work within. (n=60) 2% 22% 3 enhance my reimbursement if I meet their threshold. (n=33) 2 2 12% decrease my reimbursement if I don t meet their threshold. (n=29) 2 21% 3 I am not expected by the organization I work within, to comply with any set guidelines or pathways when treating nonsquamous NSCLC patients. (n=71) 11% 11% 11% 1 2 Note: Percentages may not total 100 because of rounding. Page 9
Q3. Which statement best reflects your use of guidelines or pathways when treating 1st line, stage IV, non-squamous NSCLC patients? (select all that apply) Limited guideline or pathway is defined as 3 options or less for a specific cancer. (e.g.: Stage IV, non-squamous NSCLC) By Practice Size 1 to 3 4 to 9 10 or more our practice approved pathway. (n=254) 2 2 52% an approved guideline for the hospital I work within. (n=192) 20% 2 5 an approved guideline for the accountable care organization (ACO) I work within. (n=60) 2 1 5 enhance my reimbursement if I meet their threshold. (n=33) 12% 4 3 decrease my reimbursement if I don t meet their threshold. (n=29) 1 24% 5 I am not expected by the organization I work within, to comply with any set guidelines or pathways when treating nonsquamous NSCLC patients. (n=71) 2 5 Note: Percentages may not total 100 because of rounding. Page 10
Q3. Which statement best reflects your use of guidelines or pathways when treating 1st line, stage IV, non-squamous NSCLC patients? (select all that apply) Limited guideline or pathway is defined as 3 options or less for a specific cancer. (e.g.: Stage IV, non-squamous NSCLC) By Practice Setting Academic Setting Community Setting our practice approved pathway. (n=249) 4 5 an approved guideline for the hospital I work within. (n=190) 61% 3 an approved guideline for the accountable care organization (ACO) I work within. (n=58) 5 4 enhance my reimbursement if I meet their threshold. (n=33) 4 5 decrease my reimbursement if I don t meet their threshold. (n=28) 5 4 I am not expected by the organization I work within, to comply with any set guidelines or pathways when treating nonsquamous NSCLC patients. (n=71) 51% 4 Page 11
Q3. Which statement best reflects your use of guidelines or pathways when treating 1st line, stage IV, non-squamous NSCLC patients? (select all that apply) Limited guideline or pathway is defined as 3 options or less for a specific cancer. (e.g.: Stage IV, non-squamous NSCLC) By Specialty Medical Oncology Radiation Oncology Surgical Oncology Internal Medicine General Surgery Other our practice approved pathway. (n=254) 5 2% 12% an approved guideline for the hospital I work within. (n=192) 40% 2 2% an approved guideline for the accountable care organization (ACO) I work within. (n=60) 4 30% enhance my reimbursement if I meet their threshold. (n=33) 64% decrease my reimbursement if I don t meet their threshold. (n=29) 62% 24% I am not expected by the organization I work within, to comply with any set guidelines or pathways when treating nonsquamous NSCLC patients. (n=71) 5 1 Note: Percentages may not total 100 because of rounding. Page 12
NCCN TRENDS Results: January 2013 NCCN Trends is an analytics tool from the National Comprehensive Cancer Network (NCCN ) that surveys how clinicians across the U.S. and around the globe are delivering cancer care. NCCN Trends surveys are designed to reach targeted populations that can include several thousand clinicians as a potential sample size. NCCN can also provide analytics on existing NCCN Trends and clinician demographic data sets, allowing for greater insight into oncology practice patterns. To commission an NCCN Trends survey, to discuss analytic and data services, or to request information on other NCCN programs and resources, please contact: Christine MacCracken, MSHEd, BSN Senior Director, Business Insights 215.690.0557 maccracken@nccn.org National Comprehensive Cancer Network (NCCN ) The National Comprehensive Cancer Network (NCCN ), a not-for-profit alliance of 21 of the worldês leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives. 275 Commerce Drive Suite 300 Fort Washington, PA, 19034 Telephone: 215.690.0300 Fax: 215.690.0280 NCCN.org - For Clinicians NCCN.com - For Patients * All NCCN Trends survey content and resulting data are owned by NCCN. Survey responses are made anonymous to protect the privacy of survey respondents. NCCN may license survey content, data, and analytic results to third parties, but retains the rights to use this data for other purposes, including the support of educational and research efforts or for other strategic or business purposes. Complex C-N-1296-0213 Page 13